Keith Norris to Hyperparathyroidism, Secondary
This is a "connection" page, showing publications Keith Norris has written about Hyperparathyroidism, Secondary.
Connection Strength
0.980
-
Norris KC. Oral paricalcitol : a viewpoint by keith C. Norris. Treat Endocrinol. 2006; 5(5):326-7.
Score: 0.246
-
Bishop CW, Ashfaq A, Choe J, Strugnell SA, Johnson LL, Norris KC, Sprague SM. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
Score: 0.236
-
Ashfaq A, Choe J, Strugnell SA, Patel N, Sprague SM, Norris KC, Lerma E, Petkovich PM, Bishop CW, Ashfaq A. Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
Score: 0.231
-
Omije D, Norris K, Wang J, Pan D, Kermah D, Gupta A. Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of Blacks and Hispanics. Clin Nephrol. 2008 Oct; 70(4):312-8.
Score: 0.074
-
Friedman TC, Norris KC. The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab. 2002 Jul; 13(5):189-94.
Score: 0.048
-
Maung HM, Elangovan L, Fraz?o JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001 Mar; 37(3):532-43.
Score: 0.044
-
Fraz?o JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000 Sep; 36(3):550-61.
Score: 0.042
-
Coburn JW, Norris KC, Sherrard DJ, Bia M, Llach F, Alfrey AC, Slatopolsky E. Toxic effects of aluminum in end-stage renal disease: discussion of a case. Am J Kidney Dis. 1988 Sep; 12(3):171-84.
Score: 0.018
-
Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008 Jul; 19(7):1379-88.
Score: 0.018
-
Kleeman CR, Norris K, Coburn JW. Is the clinical expression of primary hyperparathyroidism a function of the long-term vitamin D status of the patient? Miner Electrolyte Metab. 1987; 13(5):305-10.
Score: 0.016
-
Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis. 1990 Aug; 16(2):126-32.
Score: 0.005